228. Bronchiolitis obliterans
92 clinical trials,   125 drugs   (DrugBank: 34 drugs),   33 drug target genes,   152 drug target pathways
Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03674047 (ClinicalTrials.gov) | April 19, 2019 | 14/9/2018 | Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | Other Cancer | Drug: ruxolitinib | Massachusetts General Hospital | Incyte Corporation | Recruiting | 18 Years | 75 Years | All | 50 | Phase 2 | United States |